Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05275075 · ClinicalTrials.gov registry record
Identify microRNAs in Cachexia in Pancreatic Carcinoma
A clinical trial of Resectable Pancreatic Adenocarcinoma, sponsored by University of Oklahoma.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT05275075 is a study of Resectable Pancreatic Adenocarcinoma that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 100 participants, below the 118-participant average among 5 other Resectable Pancreatic Adenocarcinoma trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05275075, a study of Resectable Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.
Conditions Studied
Interventions
- OTHER Pancreatic cancer microRNA and messenger RNA expression.
Study Locations (1)
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-12-07 |
| Est. Completion | 2029-05-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05275075
The ClinicalTrials.gov registry entry for NCT05275075 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 118-participant average among 5 other Resectable Pancreatic Adenocarcinoma trials with a reported enrollment target (15% lower). The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Resectable Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Pancreatic cancer microRNA and messenger RNA expression. is the first listed.
NCT05275075 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.
Frequently Asked Questions
What is clinical trial NCT05275075 about?
NCT05275075 is a clinical study titled "Identify microRNAs in Cachexia in Pancreatic Carcinoma". The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.
What is the current status of trial NCT05275075?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2022-12-07. Estimated completion is 2029-05-01.
What conditions does trial NCT05275075 study?
This clinical trial studies the following conditions: Resectable Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT05275075?
The interventions under investigation include: Pancreatic cancer microRNA and messenger RNA expression. (OTHER).
Who is sponsoring clinical trial NCT05275075?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05275075 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Resectable Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
RECRUITING · Phase 2
-
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.